Results for biopharmaceuticals

Add to feed Create your own feed

Latest

Provectus Biopharmaceuticals Announces New Data from Combination Therapy Trial of Small Molecule Cancer Immunotherapy PV-10® and Keytruda® for First-Line Stage III Mel.. $PVCT

$EIGR [15s. delayed]: Issued Press Release on December 01, 05:45:00: EIGR LAWSUIT ALERT: Levi & biopharmaceuticals'>Korsinsky Notifies Eiger BioPharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

$EIGR [15s. delayed]: Issued Press Release on November 30, 05:45:00: SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eiger BioPharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 9, 2023 - (NASDAQ: EIGR)

$EIGR [15s. delayed]: Issued Press Release on November 29, 05:45:00: EIGR ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of January 9, 2023 in the Class Action Filed on Behalf of biopharmaceuticals'>Eiger BioPharmaceuticals, Inc. Shareholders

biopharmaceuticals announces'>Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company& #39 ;s Phase 3 Trial in Rheumatoid Arthr.. $NAVB

$NAVB [15s. delayed]: Issued Press Release on November 28, 08:30:00: biopharmaceuticals announces'>Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company’s Phase 3 Trial in Rheumatoid Arthritis

$EIGR [15s. delayed]: Issued Press Release on November 28, 05:45:00: SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eiger BioPharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 9, 2023 - (NASDAQ: EIGR)

Provectus Biopharmaceuticals Announces Acceptance of Small Molecule Cancer Immunotherapy PV-10® Stage III Melanoma Abstract at Melanoma Bridge 20.. $PVCT

Loading
Loading

Most relevant

South Korea’s top conglomerate Samsung said that it will invest $356 billion over the next five years. The company plans to invest heavily in biopharmaceuticals, with a view to making it as successful as its chip division

#COVID19 | Pune based biopharmaceuticals'>Gennova Biopharmaceuticals has submitted phase 2 data of mRNA vaccine & has also completed the recruitment of phase 3 data. Drugs Controller General of India's (DCGI) Subject Expert Committee (SEC) is expected to review the data soon: Official sources

tweet picture

biopharmaceuticals'>Gennova Biopharmaceuticals has also developed the mRNA vaccine for the #Omicron  variant that will be tested on humans for efficacy & immunogenicity soon: Official sources

A potential #COVID19  vaccine from China's biopharmaceuticals'>Clover Biopharmaceuticals was 67% effective against COVID-19 of any degree of severity and 79% against the highly infectious #Delta  variant in a large trial, the company said on Wednesday. (Reuters)

tweet picture

New #COVID19  vaccine developed by China's biopharmaceuticals'>Clover Biopharmaceuticals has proven to be 67% effective against COVID-19, and 79% against the Delta variant in a mass clinical trial, Reuters reports

tweet picture

A Covid-19 vaccine developed by biopharmaceuticals'>Sichuan Clover Biopharmaceuticals was found to prevent 79% of cases of any severity caused by the delta variant in late-stage trials

SK Biopharmaceuticals surged to more than double the company’s initially offered price during its trading debut to become an $8 billion stock

We’re contributing to the global response to #COVID19  and supporting the development of candidate vaccines by providing our adjuvant technology to China-based Clover Biopharmaceuticals. Learn more: #coronavirus 

China to plow big money into emerging industries ranging from artificial intelligence to biopharmaceuticals

tweet picture

We're emphasising innovation in New Chemical Entities, Generics, BioPharmaceuticals & the latest - Phytopharmaceutical drugs; to stay global

Loading
Loading